The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?
We investigated the off-patent biological market in Belgium from a policy maker’s perspective, in light of the Belgian pharmaceutical health system. The main barriers relate to a short-term budgetary focus, to the overwhelming innovator’s reach and to a concertation model with assessment and appraisal being mixed which results in poorly effective policy measures.
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Reihe/Periodikum: | Pharmaceuticals, Vol 14, Iss 352, p 352 (2021) |
Verlag/Hrsg.: |
MDPI AG
|
Schlagwörter: | biosimilar / reference biological / competitive market / Belgium / Medicine / R / Pharmacy and materia medica / RS1-441 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26612296 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.3390/ph14040352 |